You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Nordisk
since
auto-detected in 113 stories
3 days ago
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades ⊖
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
4 days ago
Novo Nordisk shares drop 10% after poor weight loss trial result ⊖⊖
Once-a-week injection achieved weight loss of 23%, which is lower than some existing treatments
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial ⊖
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
16 days ago
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start ⊕
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs ⊕
Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.
17 days ago
Wegovy maker sues rival over 'knock-off' weight-loss drugs ⊖
Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".
18 days ago
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections ⊖
Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.
Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill ⊕
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.
20 days ago
Hims & Hers abandons copycat weight-loss drug in face of FDA probe ⊖
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy